

Online resource 5 – Analyses within the IDH mutant/1p/19q non-co-deleted subgroup (n=264)

Title

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas

Acta Neuropathologica

Authors: Adriana Olar, Khalida M. Wani, Kristin Diefes, Lindsey E. Heathcock, Hinke F. van Thuijl, Mark R. Gilbert, Terri S. Armstrong, Erik P. Sulman, Daniel P. Cahill, Elizabeth Vera-Bolanos, Ying Yuan, Jaap C. Reijneveld, Bauke Ylstra, Pieter Wesseling, Kenneth D. Aldape

Corresponding authors:

Adriana Olar, MD

The University of Texas MD Anderson Cancer Center

Dept. of Pathology, G1.3510

1515 Holcombe Blvd.

Houston, TX, 77030, USA

Email: adriana_olar@yahoo.com

Kenneth Aldape, MD



Princess Margaret Cancer Centre and Ontario Cancer Institute

610 University Ave

Toronto, ON M5G 2M9, Canada

Email: ken.aldape@uhnresearch.ca

Figure S5: Overall survival among IDH mutated and 1p/19q non-co-deleted diffuse gliomas (n=264) stratified by WHO grade (A), mitotic index subgroups (B), and by age subgroups (C). Note: all reported p values are log-rank.






Table S5: Cox multivariate analysis among 205 IDH mutant, 1p/19q co-deleted cases on which adjuvant treatment data were available; with mitotic index (A) and with WHO grade (B). CI-confidence interval.

A	Variable	p-value	Hazard Ratio	95% CI
	Mitotic index (high vs. low)	0.3202	1.28	0.79-2.09
	Age	0.7981	1.00	0.98-1.02
	Adjuvant chemotherapy (yes vs. no)	0.430	0.84	0.55-1.29
	Adjuvant radiation (yes vs. no)	0.063	0.62	0.37-1.03
B	Variable	p-value	Hazard Ratio	95% CI
	WHO grade (III vs. II)	0.4969	1.17	0.74-1.86
	Age	0.8703	1.00	0.98-1.02
	Adjuvant chemotherapy (yes vs. no)	0.2988	0.80	0.52-1.22
	Adjuvant radiation (yes vs. no)	0.1527	0.67	0.39-1.16